Post hoc analysis of the phase 2 AURA trial (88 patients with muscle-invasive bladder cancer, radical cystectomy): complications 52%; major complications were more frequent after neoadjuvant chemo-immunotherapy than avelumab alone (21.2% vs 15.4%, p=0.03; non-randomised).
Secondary analysisn = 88
Mjaess et al. Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004)